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A B S T R A C T
Factor VII (FVII) deficiency is the most common among the rare bleeding disorders, which is caused by mutations in coagulation factor VII. Clinical features caused
by FVII deficiency vary from mild or asymptomatic to fatal cerebral hemorrhage. We generated an induced pluripotent stem cell (iPSC) line, YCMi002-A, from FVII
deficiency patient-derived fibroblasts. YCMi002-A cells are characterized by novel compound heterozygous mutations. The c.345C > A; p.C115X is well known and
the second one, c.1276C > T; p.Q426X, remains novel. YCMi002-A cells may help researchers to understand correlation between these mutations and the symptoms
of FVII deficiency.
1. Resource Table










Type of cell line iPSC
Origin Human







Transgene free (episomal plasmid)
Genetic Modification YES
Type of Modification Hereditary
Associated disease Factor VII Deficiency
Gene/locus F7 (NM_000131.4) - c.345C > A, c.1276C > T / 13q34
Method of modification N/A






Date archived/stock date Feb. 2020
Cell line repository/bank https://hpscreg.eu/cell-line/YCMi002-A
Ethical approval Ethical committee: Yonsei university health system,
Severance Hospital, Institutional review board approval
number: #4–2012-0028
2. Resource utility
Novel iPSCs were derived from an FVII compound heterozygous
patient with two mutations, one well-known and one novel. These
iPSCs may be helpful to study the correlation between the severity of
FVII deficiency and mutations.
3. Resource details
Factor VII (FVII) deficiency is the most frequent among rare
bleeding disorders. It is usually transmitted in an autosomal recessive
manner with an incidence of one per 500,000 in the general population
(Perry, 2002). Clinical symptoms are heterogeneous and range from
miscellaneous minor bleeding to severe life-threatening hemorrhages,
such as cerebral, gastrointestinal, and joint hemorrhages (Lapecorella
et al., 2008). Various types of mutations are responsible for FVII defi-
ciency, however, most of them are point mutations (The F7 mutations
database, http://www.umd.be/F7/W_F7/index.html). In this study, we
generated an induced pluripotent stem cell (iPSC) line, YCMi002-A,
from a female patient carrying a novel nonsense mutation. We repro-
grammed patient-derived fibroblasts into iPSCs using integration-free
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episomal plasmids expressing five pluripotency factors (OCT4, SOX2,
KLF4, L-MYC, and Lin28). After the induction of iPSC, we picked sev-
eral iPSC colonies with a normal human embryonic stem-cell (hESC)
like morphology (Fig. 1A). After selection, we checked the expressions
of several pluripotency markers by immunostaining. These colonies
highly expressed the pluripotency markers (OCT4, SOX2, and NANOG),
and the surface markers (SSEA4, TRA-1-81, and TRA-1-60) (Fig. 1D).
The expression level of pluripotency markers measured using quanti-
tative-polymerase chain reactions (PCR) in YCMi002-A was similar to
human embryonic stem cell H9 (Fig. 1C). Pluripotency was further
evaluated by differentiation of three germ layers. Using embryoid body
(EB) formation assay, we demonstrated that YCMi002-A cells could be
differentiated into the principal cells in three germ layers with ex-
pression of ectodermal marker Nestin, endodermal marker Sox17, and
Fig. 1. Characterization of YCMi002-A iPSC line.
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mesodermal marker α-SMA (Fig. 1E). We identified heterozygous
compound mutations in YCMi002-A by Sanger sequencing (Fig. 1B).
The first mutation is a well-known mutant located in exon 5 of Factor
VII (c.345C > A; p.C115X), and the other is novel and located in exon
9 (c.1276C > T; p.Q426X). We checked for remaining episomal
plasmids in YCMi002-A using PCR with episomal plasmid-specific pri-
mers. We did not detect the episomal plasmids after passage 16 or in-
sertion into established YCMi002-A (Fig. 1F, Day 3 (D3) for positive
control). YCMi002-A cells showed a normal 46, XX karyotype after 16
passages in culture (Fig. 1G). Short tandem repeat (STR) analysis was
performed on genomic DNA extracted from YCMi002-A cells and par-
ental fibroblasts. We found an exact match in all the 18 STR loci ana-
lyzed, which shows that the cell line was not contaminated by any other
human cell lines and genetically identical with parental fibroblasts
(submitted in archive with journal). YCMi002-A cells were shown to be
free of mycoplasma contamination (supplementary data).
4. Materials and methods
4.1. Cell culture & generation of iPSCs
Episomal plasmids encoding reprogramming factors were used as
reported (Okita et al., 2011). In brief, patient-derived fibroblasts grown
in DMEM supplemented with 10% FBS and 1% NEAA were electro-
porated using a microporator system (Neon, Thermo Fisher Scientific)
with 3 μg of episomal plasmid mixtures. After three 10 ms pulse with a
voltage of 1,650, the cells were grown in DMEM containing 10% FBS
and 1% NEAA. Seven days after transfection, cells were transferred onto
a STO feeder layer. iPSC colonies like hESCs were picked up me-
chanically and further cultured for characterization (Table 1).
4.2. RNA extraction, cDNA synthesis, and qPCR
Total RNA was extracted using the Easy-Spin® Total RNA Extraction
kit (iNtRON Biotechnology) according to the manufacturer's instruc-
tions. cDNA was synthesized from 1 μg of total RNA using
PrimeScriptTM RT Master Mix (TAKARA Bio Inc.). qPCR was performed
using FastFire qPCR PreMix (TIANGEN) in a CFX96 Real-Time System
(Bio-Rad). The transcription level for each targeted gene was normal-
ized to GAPDH expression. Primer sequences are listed in Table 2.
4.3. PCR
Total genomic DNA was extracted from YCMi002-A cells and par-
ental fibroblasts by DNeasy Blood & Tissue kit (Qiagen). PCR was
performed by a PCR thermal cycler (Applied Biosystems Geneamp
2720) using EmeraldAmp® GT PCR Master Mix (TAKARA Bio Inc.) ac-
cording to the manufacturer's instructions.
4.4. Immunocytochemistry
Cells were fixed with 4% paraformaldehyde for 15 min at room
temperature. After permeabilization with 0.1% Triton X-100 in PBS,
cells were blocked with 2% BSA-PBS for 1 h at room temperature, and
incubated overnight at 4 °C with primary antibodies in 2% BSA-PBS
(Table 2). Cell were then washed, labeled with fluorescence-tagged
secondary antibodies (Thermo Fisher Scientific) for 30 min at room
temperature and mounted in DAPI mounting medium (Vector Labora-
tories). Images were obtained with an Olympus IX71 microscope
equipped with a DP71 digital camera (Olympus FSX100 system).
4.5. Differentiation into three germ layers
To test the differentiation of YCMi002-A cells in vitro, embryoid
bodies (EBs) were formed by partial dissociation and cultured in
DMEM/F12 (1:1) medium supplemented with 20% knockout serum
(Invitrogen), 4.5 g/L L-glutamine, 1% NEAA, 0.1 mM 2-mercap-
toethanol, and 15% FBS. 7 days after induction, EBs were attached onto
Matrigel-coated culture dishes and further cultured for 14 days.
Spontaneous differentiation of EBs into the three germ layer lineages
was detected by immunostaining with appropriate antibodies (Table 2).
4.6. Karyotyping and mycoplasma testing
G-banding karyotype analysis was performed at passage 16 at
GenDix, Inc. using standard protocols for GTG banding. Total 20 me-
taphases were analyzed at 550 band resolution. The absence of myco-
plasma contamination was tested by e-Myco™ Mycoplasma PCR
Detection Kit (iNtRON Biotechnology).
4.7. STR analysis
STR assay was performed by Cosmogenetech co, Ltd. (Korea).
Briefly, the target loci were amplified using PowerPlex® 18D System Kit
(Promega) and analyzed with ABI3130xl genetic analyzer (Applied




Classification Test Result Data
Morphology Photography Normal Fig. 1 panel A
Phenotype Qualitative analysis
Immunocytochemistry
Positive for pluripotency markers including OCT4, SOX2,
NANOG, SSEA4, TRA-1-81, and TRA-1-60
Fig. 1 panel D
Quantitative analysis RT-qPCR Positive for pluripotency markers including OCT4, SOX2,
NANOG, TET1, REX1
Fig. 1 panel C
Genotype Karyotype (G-banding) and resolution 46, XX Resolution 550 Fig. 1 panel G
Identity Microsatellite PCR (mPCR) OR N/A
STR analysis 18 sites were tested and all matched submitted in archive with
journal
Mutation analysis (IF APPLICABLE) Sequencing Compound Heterozygote Fig. 1 panel B
Southern Blot OR WGS N/A
Microbiology and virology Mycoplasma Mycoplasma testing via PCR. Negative supplementary
Differentiation potential Embryoid body formation NESTIN (ectoderm);
Sox17 (endoderm);
α-SMA (mesoderm)
Fig. 1 panel E
Donor screening (OPTIONAL) HIV 1 + 2 Hepatitis B, Hepatitis C N/A
Genotype additional info
(OPTIONAL)
Blood group genotyping N/A
HLA tissue typing N/A
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Antibodies used for immunocytochemistry/flow-citometry
Antibody Dilution Company Cat # and RRID
Pluripotency markers Rabbit anti-OCT4 1:200 Santa Cruz, cat #sc-9081, RRID:AB_2167703
Rabbit anti-SOX2 1:200 Millipore, cat # AB5603 RRID:AB_304980
Goat anti-NANOG 1:50 R&D systems, cat #AF1997 RRID:AB_355097
Mouse anti-SSEA4 1:200 Millipore, cat #MAB4304 RRID:AB_177629
Mouse anti-TRA-1-81 1:100 Millipore, cat #MAB4381 RRID:AB_177638
Mouse anti-TRA-1-60 1:100 Millipore, cat #MAB4360 RRID:AB_2277963
Differentiation markers Rabbit anti-NESTIN 1:1000 Millipore, cat #ABD69 RRID:AB_2744681
Goat anti-SOX17 1:200 Santa Cruz, cat#sc-17356 RRID:AB_2195655
Mouse anti-α-SMA 1:400 Sigma-Aldrich, cat #A5228 RRID:AB_262054
Secondary antibodies Donkey anti-rabbit IgG (H + L) highly cross-adsorbed secondary
antibody, Alexa Fluor 488
1:1000 Invitrogen, cat #A-21206 RRID:AB_2535792
Donkey anti-goat IgG (H + L) cross-adsorbed secondary antibody,
Alexa Fluor 488
1:1000 Invitrogen, cat #A-11055 RRID:AB_2534102
Donkey anti-mouse IgG (H + L) highly cross-adsorbed secondary
antibody, Alexa Fluor 488
1:1000 Invitrogen, cat #A-21202 RRID:AB_141607
Donkey anti-mouse IgG (H + L) highly cross-adsorbed secondary
antibody, Alexa Fluor 594
1:1000 Invitrogen, cat #A-21203 RRID:AB_141633
Donkey anti-goat IgG (H + L) cross-adsorbed secondary antibody,
Alexa Fluor 594
1:1000 Invitrogen, cat #A-11058 RRID:AB_2534105
Donkey anti-rabbit IgG (H + L) highly cross-adsorbed secondary
antibody, Alexa Fluor 594
1:1000 Invitrogen, cat #A-21207 RRID:AB_141637
Primers
Target Forward/Reverse primer (5′-3′)
Episomal vector (PCR) EBNA-1 (128 bp) ATGGACGAGGACGGGGAAGA/ GCCAATGCAACTTGGACGTT
Pluripotency markers (qPCR) OCT4 (164 bp) CCTCACTTCACTGCACTGTA / CAGGTTTTCTTTCCCTAGCT
SOX2 (80 bp) TTCACATGTCCCAGCACTACCAGA / TCACATGTGTGAGAGGGGCAGTGTGC
NANOG (154 bp) TGAACCTCAGCTACAAACAG / TGGTGGTAGGAAGAGTAAAG
TET1 (165 bp) CTGCAGCTGTCTTGATCGAGTTAT / CCTTCTTTACCGGTGTACACTACT
REX1 (145 bp) TCACAGTCCAGCAGGTGTTTG / TCTTGTCTTTGCCCGTTTCT
House-Keeping Genes (PCR) GAPDH (327 bp) GAACATCATCCCTGCCTCTACTG/ CAGGAAATGAGCTTGACAAAGTGG
House-Keeping Genes (qPCR) GAPDH (159 bp) CAATGACCCCTTCATTGACC / TTGATTTTGGAGGGATCTCG
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